2. Search Result
Search Result
Results for "

Parkinson model

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

3

Peptides

9

Natural
Products

2

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124876
    SynuClean-D

    SC-D

    		 α-synuclein Neurological Disease
    SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .
    SynuClean-D
  • HY-15608
    MPTP hydrochloride
    Maximum Cited Publications
    36 Publications Verification

    		 Dopamine Receptor Apoptosis Neurological Disease Cancer
    MPTP hydrochloride is a brain penetrant dopamine neurotoxin. MPTP hydrochloride can be used to induces Parkinson’s Disease model. MPTP hydrochloride, a precusor of MPP +, induces apoptosis . MPTP hydrochloride has been verified by MCE with professional biological experiments.
    MPTP hydrochloride
  • HY-10888
    Istradefylline
    5+ Cited Publications

    KW-6002

    		 Adenosine Receptor Neurological Disease
    Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
    Istradefylline
  • HY-102024
    A2A receptor antagonist 1

    CPI-444 analog

    		 Adenosine Receptor Neurological Disease Cancer
    A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A2A receptor and A1 receptor with Ki values of 4 and 264 nM, respectively .
    A2A receptor antagonist 1
  • HY-N10283
    Neoechinulin C

    		Endogenous Metabolite Neurological Disease
    Neoechinulin C, an echinulin-related indolediketopiperazine alkaloid, protects the neuronal cells against paraquat-induced damage in a Parkinson’s disease model .
    Neoechinulin C
  • HY-161502
    DHX-SP

    		Fluorescent Dye Others
    DHX-SP is a fluorescent probe, which visualizes superoxide anion (O2 ·–) and peroxynitrite (ONOO –) during ferroptosis of PC12 cells and in the Parkinson’s disease model .
    DHX-SP
  • HY-119857
    AGK7

    SIRT2 Inhibitor,Inactive Control

    		 Sirtuin Neurological Disease
    AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .
    AGK7
  • HY-106430
    Piclozotan

    SUN N4057

    		 5-HT Receptor Neurological Disease
    Piclozotan (SUN N4057) is a 5HT1A receptor agonist. Piclozotan improves motor complications in Parkinson's disease model .
    Piclozotan
  • HY-N12657
    Retinestatin

    		Others Neurological Disease
    Retinestatin, a new polyol polyketide, can protect SH-SY5Y dopaminergic cells from MPP + (HY-W008719)-induced cytotoxicity. Retinestatin shows neuroprotective effects in an in vitro model of Parkinson’s disease .
    Retinestatin
  • HY-162573
    Monoamine Oxidase B inhibitor 5

    		Monoamine Oxidase Neurological Disease
    Monoamine Oxidase B inhibitor 5 (Compound 16d) is a selective and reversible inhibitor for monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki of 82.5 nM. Monoamine Oxidase B inhibitor 5 exhibits good pharmacokinetic characters and weak toxicity in rats model. Monoamine Oxidase B inhibitor 5 alleviates MPTP-induced (HY-15608) motor impairment in Parkinson’s mouse model. Monoamine Oxidase B inhibitor 5 is blood-brain barrier (BBB) penetrate .
    Monoamine Oxidase B inhibitor 5
  • HY-135387
    4-Desmethyl Istradefylline

    		Drug Metabolite Neurological Disease
    4-Desmethyl Istradefylline is a metabolite of Istradefylline. 4-Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease .
    4-Desmethyl Istradefylline
  • HY-123556
    SZV-558

    		Monoamine Oxidase Neurological Disease
    SZV-558 is a potent and selective MAO-B inhibitor with IC50 values of 50 and 60 nM for rats and humans, respectively. SZV-558 can be used in studies of Parkinson's disease (PD) models .
    SZV-558
  • HY-123506
    Fenlean

    		Src Neurological Disease Inflammation/Immunology
    Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models .
    Fenlean
  • HY-10888R
    Istradefylline (Standard)

    		Adenosine Receptor Neurological Disease
    Istradefylline (Standard) is the analytical standard of Istradefylline. This product is intended for research and analytical applications. Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
    Istradefylline (Standard)
  • HY-N8730
    7,8,3′,4′-Tetramethoxyflavone

    		Others Neurological Disease
    7,8,3 ',4 '-Tetramethoxyflavone is an extract isolated from natural pomegranate juice and seeds. 7,8,3 ',4' -Tetramethoxyflavone has a protective effect on the neurotoxicity of paraquat-induced Parkinson's disease mouse model .
    7,8,3′,4′-Tetramethoxyflavone
  • HY-161163
    IND 1316

    		AMPK Neurological Disease
    IND 1316 is an orally active, blood-brain barrier permeable AMPK activator with neuroprotective effects in animal models of Huntington's disease. IND 1316 can be used for research on neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .
    IND 1316
  • HY-12629
    PF470

    PF-06297470

    		 Others Others
    PF470 (PF-06297470) is a negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) with significant efficacy in Parkinson's disease models, but clinical development was halted due to potential issues found in toxicology studies.
    PF470
  • HY-119918
    Cycrimine

    		mAChR Neurological Disease
    Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder .
    Cycrimine
  • HY-10888S
    Istradefylline-13C,d3

    KW-6002-13C,d3

    		 Isotope-Labeled Compounds Adenosine Receptor Neurological Disease
    Istradefylline- 13C,d3 is the 13C- and deuterium labeled Istradefylline. Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
    Istradefylline-13C,d3
  • HY-121152
    Chiisanoside

    		α-synuclein Apoptosis GABA Receptor Dopamine Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Chiisanoside exhibits neuroprotective, anticancer, antidepressant, anti-inflammatory, anti-obesity and anti-platelet activities. Chiisanoside inhibits tumor growth in H22 xenograft mouse model, through immunoregulation, induction of apoptosis and inhibition of angiogenesis. Chiisanoside attenuates Parkinson’s disease through regulation of Parkin/ZNF746/PGC-1α axis, and promotion of mitochondrial biogenesis .
    Chiisanoside
  • HY-161665
    BDZ-P7

    		iGluR Neurological Disease
    BDZ-P7 inhibits AMPA receptor GluA2, GluA1/2, GluA2/3, and GluA1 subunit with IC50s of 3.03 μM, 3.14 μM, 3.19 μM, 3.2 μM. BDZ-P7 has neuroprotective effect and reinstates locomotor abilities in a mouse model of Parkinson’s disease .
    BDZ-P7
  • HY-155659
    4A7C-301

    		Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    4A7C-301 is a Nurr1 agonist with robust neuroprotective effects in vitro. 4A7C-301 significantly ameliorates neuropathological abnormalities and improves motor and olfactory dysfunctions in AAV2-mediated α-synuclein-overexpressing male mouse models. 4A7C-301 can be used for the research of Parkinson’s disease .
    4A7C-301
  • HY-119274
    BN-82451 dihydrochloride

    		Others Neurological Disease
    BN-82451 dihydrochloride, an orally active and CNS-penetrated antioxidant and a multitargeting neuroprotective agent, exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis .
    BN-82451 dihydrochloride
  • HY-W116433
    SK609

    		Others Neurological Disease
    SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease .
    SK609
  • HY-160604
    Remacemide

    FPL 12924; PR 934-423; FPL 13592

    		 iGluR Neurological Disease
    Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research .
    Remacemide
  • HY-148794
    Risvodetinib

    IkT-148009

    		 c-Met/HGFR Bcr-Abl Neurological Disease Cancer
    Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .
    Risvodetinib
  • HY-110157
    AC-186

    		Estrogen Receptor/ERR Neurological Disease
    AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC50s of 6 nM and 5000 nM for ERβ and ERα, respectively. AC-186 shows gender selective neuroprotective effects in a male rat model of Parkinson's disease .
    AC-186
  • HY-115796
    VU0477886

    		Others Others
    VU0477886 is a metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator with potent activating activity on mGlu4 (EC50 = 95nM, 89% Glu Max), good pharmacokinetic characteristics (brain: plasma Kp = 1.3), and significant therapeutic efficacy in Parkinson's disease models.
    VU0477886
  • HY-119378
    AK 295

    CX 295

    		 Proteasome Apoptosis Neurological Disease
    AK 295 (CX 295) is a calpain inhibitor that inhibits apoptosis through a calpain-dependent pathway. AK 295 improves neurological function in a rat model of spinal cord injury (SCI). AK 295 can be used in the study of neurodegenerative diseases, such as bulbar amyotrophy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis .
    AK 295
  • HY-P3247
    [D-Ala2]-GIP (human)

    		Insulin Receptor Neurological Disease Metabolic Disease
    [D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
    [D-Ala2]-GIP (human)
  • HY-131592
    Tricetin

    		Apoptosis Keap1-Nrf2 Neurological Disease Inflammation/Immunology Cancer
    Tricetin is a potent competitive inhibitor of the Keap1-Nrf2 Protein Protein Interaction (PPI). Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway .
    Tricetin
  • HY-107811
    Harmol
    1 Publications Verification

    		 Monoamine Oxidase Autophagy Apoptosis α-synuclein Cardiovascular Disease Neurological Disease Cancer
    Harmol is a TFEB activator, an orally active monoamine oxidase inhibitor that has anti-tumor, anti-depressant, and anti-aging effects. Harmol can induce cell mitosis, autophagy and apoptosis. Harmol promotes the degradation of α-synuclein through the regulation of the autophagy-lysosomal pathway, improving motor deficits in mouse models of Parkinson's disease .
    Harmol
  • HY-153091
    BMY 14802

    		Adrenergic Receptor 5-HT Receptor Sigma Receptor Neurological Disease
    BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM .
    BMY 14802
  • HY-149065
    D-685

    		α-synuclein Neurological Disease
    D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration .
    D-685
  • HY-118956
    Adrogolide hydrochloride

    ABT-431 hydrochloride; DAS-431 hydrochloride

    		 Dopamine Receptor Neurological Disease
    Adrogolide hydrochloride (ABT-431 hydrochloride) is a chemically stable prodrug that can convert to the dopamine D1 receptor agonist A-86929. Adrogolide hydrochloride ameliorates the MPTP (HY-15608)-induced Parkinson's Disease in marmoset model, reduces the dyskinesias tendency. Adrogolide hydrochloride reverses Risperidone (HY-11018)-induced cognitive deficits in monkey .
    Adrogolide hydrochloride
  • HY-149941
    hNTS1R agonist-1

    		Neurotensin Receptor Neurological Disease
    hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (Ki: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent .
    hNTS1R agonist-1
  • HY-B0581
    Dexrazoxane
    5+ Cited Publications

    ICRF-187; ADR-529; NSC-169780

    		 Ferroptosis Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .
    Dexrazoxane
  • HY-W008719
    MPP+ iodide
    10+ Cited Publications

    		 Mitochondrial Metabolism Neurological Disease
    MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
    MPP+ iodide
  • HY-156438
    NT-0796

    		NOD-like Receptor (NLR) Interleukin Related Neurological Disease
    NT-0796 is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. NT-0796 inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM. NT-0796 is an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. NT-0796 is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .
    NT-0796
  • HY-120419
    PF9601N

    		Monoamine Oxidase Neurological Disease
    PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PF9601N
  • HY-W010201
    Citronellol
    2 Publications Verification

    (±)-Citronellol; (±)-β-Citronellol

    		 Reactive Oxygen Species ERK PI3K TNF Receptor Atg8/LC3 p62 Apoptosis Necroptosis Autophagy Fungal Cardiovascular Disease Neurological Disease Cancer
    Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol
  • HY-15344
    Ketone monoester
    2 Publications Verification

    		 Others Neurological Disease Metabolic Disease
    Ketone monoester is an orally available ketone monoester that serves as a source of nutritional ketones. Ketone monoester increases plasma beta-hydroxybutyrate, acetoacetate, blood glucose, blood sodium, and blood creatinine levels in mouse models. Ketone monoester has the potential to improve athletic performance and endurance in animals. Ketone monoester partially prevents myasthenia in septic mice. Ketone monoester may also be used to study Parkinson's disease or diabetes .
    Ketone monoester
  • HY-169156
    HDAC6-IN-49

    		HDAC Monoamine Oxidase Cholinesterase (ChE) Histamine Receptor 5-HT Receptor Neurological Disease
    HDAC6-IN-49 (Compound 3) is an inhibitor for HDAC with IC50 of 0.012 and 0.735 μM for HDAC6 and HDAC1. HDAC6-IN-49 also exhibits inhibitory activities against MAO-B, cholinesterase (ChE), histamine receptor (H3R) and serotonin 6 receptor (5-HT6R). HDAC6-IN-49 exhibits neuroprotective efficacy on SH-SY5Y cell. HDAC6-IN-49 improves cognitive function and locomotor ability in Drosophila Parkinson's disease models and in C. elegans Alzheimer's disease models .
    HDAC6-IN-49
  • HY-11052A
    Trap-101 hydrochloride

    		Opioid Receptor Neurological Disease
    Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ 35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases .
    Trap-101 hydrochloride
  • HY-120553
    B-355252

    		Apoptosis Neurological Disease
    B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .
    B-355252
  • HY-W008719S
    MPP+-d3(iodide)

    		Mitochondrial Metabolism Neurological Disease
    MPP+-d3 (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT)[1][2].
    MPP+-d3(iodide)
  • HY-W010201R
    Citronellol (Standard)

    (±)-Citronellol (Standard); (±)-β-Citronellol (Standard)

    		 Reactive Oxygen Species ERK PI3K TNF Receptor Atg8/LC3 p62 Apoptosis Necroptosis Autophagy Fungal Cardiovascular Disease Neurological Disease Cancer
    Citronellol (Standard) is the analytical standard of Citronellol. Citronellol (Standard) is an orally active inducer of apoptosis. Citronellol (Standard) can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol (Standard) can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol (Standard) can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol (Standard) exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol (Standard)
  • HY-B0596
    Taltirelin

    TA-0910

    		 Thyroid Hormone Receptor Apoptosis Neurological Disease Endocrinology
    Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC50 at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca 2+ concentration (Ca 2+ release) with an EC50 value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .
    Taltirelin
  • HY-149483
    CVN417

    		nAChR Neurological Disease
    CVN417 is an orally active α6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC50s of 0.086 μM (α6), 2.56 μM (α3) and 0.657 μM (α4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinson's disease .
    CVN417
  • HY-109139A
    Taminadenant mesylate

    NIR178 mesylate; PBF509 mesylate

    		 Adenosine Receptor Cancer
    Taminadenant mesylate (NIR178 mesylate) is a potent adenosine A2A receptor antagonist with potential anti-tumor activity. Taminadenant mesylate can selectively bind and inhibit A2AR on T lymphocytes, thereby releasing adenosine/A2AR-mediated inhibition of T lymphocytes and activating T cell-mediated immune responses against tumor cells. Taminadenant mesylate works by reducing the proliferation of susceptible tumor cells. Taminadenant mesylate also showed effectiveness in reversing dyskinesias in Parkinson's disease models and was able to inhibit dyskinesias caused by L-DOPA .
    Taminadenant mesylate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: